No Data
Tengshengbo Pharmaceuticals made its first appearance at the 2024 American Association for the Study of Liver Diseases (AASLD) annual meeting to release the results of the combination of siRNA (Elebsiran) with PEG-IFNα compared to monotherapy with PEG-IFN
The 48-week treatment data from the ongoing Phase 2 ENSURE study clearly indicates that the combination of elebsiran and PEG-IFNα can provide more benefits, resulting in a higher functional cure rate. Multiple combination study data conducted by the company and its partners will continue to support the company's strategy of achieving functional HBV cure in a broader patient population through the correct combination treatment plan. Peking, china and Durham, north carolina, usa, November 19, 2024 /PRNewswire/ -- Tengsheng Bo Pharmaceutical Biotechnology Co., Ltd. ("Tengsheng Bo Pharmaceutical" or "the company",
BRII-B: 2024 Interim Report
Tengsheng Bo Medicine-B (02137) issued a total of 0.1955 million shares under the stock incentive plan on August 27th.
Tengsheng Boyao-B (02137) issued an announcement on August 16, 2024, based on the audited financial statements for the fiscal year ended June 2021...
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
Tengshengbo Medicine-B (02137.HK) expanded its mid-year loss to 0.283 billion yuan.
On August 19, Guolonghui reported that Tengshengbo Medicine-B (02137.HK) announced that for the six months ended June 30, 2024, the company's other income was 709 million yuan, a decrease of 150 million yuan or 17.5% compared with 859 million yuan for the six months ended June 30, 2023. This was mainly due to the reduction of income recognized on government subsidies. For the six months ended June 30, 2024, R&D expenses were 1,262 million yuan, compared with 2,022 million yuan for the six months ended June 30, 2023.
BRII-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
No Data
No Data
